GTM-NZNZKKM
2024 Transplant Hepatology Board Review Course
Image For Activity Cover
Availability
On-Demand
6 Courses
Cost
Member: $370.00
Non-Member: $570.00
Patient: $0.00
Associate: $210.00
Student: $120.00
Early Career: $210.00
Industry Rep: $815.00
Credit Offered
16.75 AMA PRA Category 1 Credits
16.75 ABIM MOC Points
16.75 ABP MOC Points
16.75 Attendance Credits
16.75 Participation Credits
  • Description
  • Program Agenda
  • Learning Objectives
  • Target Audience
  • Accreditation Information
  • Faculty and Disclosures
  • Privacy Policy
  • Recommended
The 2024 AASLD Transplant Hepatology Board Review Course will be released on Friday, August 30, 2024 as an on-demand course.

This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

COMPONENTS:
  • 30 online, narrated presentations 15-30 minutes in length
  • Access to a collection of 89 ABIM board-style questions with annotated answers, and option for quiz or self-study.
  • Evaluation for CME credit/ABIM and ABP MOC point offerings
DIRECTIONS: Review all section tabs before you begin. Start watching the presentation videos. Complete necessary components to claim either CME and ABIM and or ABP MOC.

CONTINUING EDUCATION: Continuing Medical Education (CME): 16.75 AMA PRA Category 1 Credits™ ABIM Maintenance of Certification (MOC): 16.75 ABIM MOC Points ABP Maintenance of Certification (MOC): 16.75 ABP MOC Points

HOW TO EARN AND CLAIM MOC POINTS
To claim both CME Credits and ABIM and or ABP MOC points for this activity you must:
• Watch each video presentation
• Complete each session post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score)
• Complete the Final Evaluation
• Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity)


COPYRIGHT: All faculty in this activity have given their permission for publication ©2024 AASLD.

Section 1 (Advanced Hepatology)

Topic

Faculty

Orientation and Test Taking Strategies

Oren K. Fix, MD, MSc, FAASLD

Portal HTN

Jacqueline (Jackie) G. O'Leary, MD, MPH

Hepatitis A, B, C, D, E Virus Infection:  Pre- and Post-Liver Transplantation

Norah Terrault, MD, MPH, FAASLD

MASLD and Liver Tx Considerations

Mary E. Rinella, M.D.

Alcohol-associated Liver Disease

Jessica L. Mellinger, MD

Metabolic and Genetic Diseases (Adult)

Michael Schilsky, MD, FAASLD

Cholestatic and Autoimmune Liver Diseases

David N. Assis, MD

Nutrition in Patients with Cirrhosis

Jennifer C. Lai, MD, MBA

Liver Disease and the Pregnant Patient

Tatyana Kushner, MD, MSCE

Acute Liver Failure (Adult)

Anne M. Larson, MD, FAASLD

Section 2 (Liver Transplantation)

Transplant Immunology

John M. Vierling, MD, FACP, FAASLD, AGAF

Immunosuppression and Rejection

Selection and Evaluation for Liver Transplantation

Lindsay Y. King, MD

Donor Selection (including Living Donor)

Shimul A. Shah, MD

Medical and Surgical Considerations of Liver Transplantation

Scott W. Biggins, MD, MAS, FAASLD

Christopher B. Hughes, MD, FACS

Recurrence of Disease After Liver Transplantation

Robert S. Brown, Jr, MD, MPH, FAASLD

Long Term Complications Post Liver Transplant

Risë Stribling, MD

Post-Liver Transplant Infectious Complications

Saima Aslam, MBBS

Section 3 (Miscellaneous)

HCC

Tamar H. Taddei, MD

Liver Neoplasms: Benign and Malignant (Non-HCC)

Julie Heimbach, MD, FAASLD

Vascular Liver Disease (Budd-Chiari, SOS)

Patrick G. Northup, MD, FAASLD

DILI

Lily Dara, MD

Ethics

Michael L Volk, MD, MSc, FAASLD

Statistics

David Goldberg, MD, MSCE

Pathology Lecture

Maura O'Neil, BS, MD

Section 4 (Pediatrics)

Pediatric Liver Tx 101

Mercedes Martinez, MD

Nathaly P. Llore, MD

Biliary Atresia & Cholestasis in Children

Amrita Narang, MD MPH

Pediatric Autoimmune Liver Disease and ALF

James E. Squires MD, MS

Metabolic and Genetic Diseases (Peds)

Richard J. Thompson, MD, PhD, FAASLD

Pediatric Liver Tumors

Arun Rangaswami, MD


  • Review the core concepts as recommended by the ABIM Blueprint for the Transplant Hepatology Board exam
  • Diagnose, manage and treat hepatobiliary disorders for the pediatric and adult population
  • Review key concepts and management of patients before, during and after liver transplantation
Hepatologists interested in studying and maintaining the ABIM hepatology review board.
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this other activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM Statement:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to [MOC point amount] MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

ABP Statement:

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 16.75 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Release Date: August 30, 2024 Expiration Date: August 30, 2026

COPYRIGHT: All faculty in this activity have given their permission for publication ©2024 AASLD.

This online, OnDemand educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards of Commercial Support by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty, and others in the planning and control of continuing medical education (CME) activities to disclose all their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education. Any relevant conflicts of interest have been mitigated.

Statement on off-label and investigational use: Faculty are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. 

Saima Aslam, MBBS:
Scientific Consultant/Advisor: Phico, Phiogen, Rocket Pharmaceuticals, BioMx, Pherecydes
Research Grants: Contrafect, Armata

David N. Assis, MD:
Research Grant: Gilead

Scott W. Biggins, MD, MAS, FAASLD:
Research Grant:
Salix

Robert S. Brown, Jr, MD, MPH, FAASLD:
Scientific Consultant/Advisor: Gilead, AbbVie, Intercept Pharmaceuticals, Salix, Mallinkrodt, eGenesis, Madrigal
Research Grants: Gilead, AbbVie, Enanta, Intercept, Mirum

Lily Dara, MD:
Scientific Consultant/Advisor: Intercept Pharmaceuticals
Research Grant: Intercept Pharmaceuticals

Oren K. Fix, MD, MSc, FAASLD:
Nothing to Disclose.

David Goldberg, MD, MSCE: 
Scientific Consultant/Advisor: Pfizer, Inc

Julie Heimbach, MD, FAASLD:
Nothing to Disclose.

Christopher B. Hughes, MD, FACS:
Nothing to Disclose.

Lindsay Y. King, MD:
Nothing to Disclose.

Tatyana Kushner, MD, MSCE:
Scientific Consultant/Advisor: Gilead, HDV, AbbVie, GlaxoSmithKline
Advisory Board: Gilead
Research Grant: Gilead

Jennifer C. Lai, MD, MBA:
Scientific Consultant/Advisor: GenFit, Boehringer/Ingelheim, NovoNordisk
Research Grants: CymaBay, AcellaHealth Inc, Lipocine, Gore Medical Vir Biotechnology

Anne M. Larson, MD, FAASLD:
Royalties/Patents:  UpToDate

Nathaly P. Llore, MD:
Nothing to Disclose.

Mercedes Martinez, MD: 
Nothing to Disclose.


Jessica L. Mellinger, MD:
Scientific Consultant:  GlaxoSmithKline

Amrita Narang, MD MPH:
Scientific Consultant/Advisor: Mirum
Speakers Bureau: Ipsen

Patrick G. Northup, MD, FAASLD:
Nothing to Disclose.

Jacqueline G. O'Leary, MD, MPH:
Scientific Consultant/Advisor: Genfit, Grifols, AbbVie, Gilead, Mallinckrodt, Astellas, NovoNordisk, Cellion, Pharmaln

Maura O'Neil, BS, MD
Nothing to Disclose.

Arun Rangaswami, MD:
Nothing to Disclose.

Mary E. Rinella, MD:
Scientific Consultant/Advisor: Boehringer Ingelheim, Intercept Pharmaceuticals, GlaxoSmithKline, Eli Lilly & Co., Inc., Madrigal, NovoNordisk, Cytodyn, HistoIndex, Sonic Incytes, Takeda Pharmaceuticals

Michael Schilsky, MD, FAASLD:
Scientific Consultant: Depymed, Arbormed, Biovie, Salix

Shimul A. Shah, MD: 
Scientific Consultant: Veloxis
Research Grants: Organ Recovery Systems, CareDx, AstraZeneca

James E. Squires MD, MS:
Scientific Consultant/Advisor: UpToDate
Data Safety Monitoring Board: Sanofi

Rise Stribling, MD:
Nothing to Disclose.

Tamar H. Taddei, MD:
Nothing to Disclose.

Norah Terrault, MD, MPH, FAASLD:
Data Safety Monitoring Board: Moderna (ended July 2022)
Scientific Consultant/Advisor: CCO Hepatitis, CLDF, Gilead Sciences (ended in 2022)

Richard J. Thompson, MD, PhD, FAASLD:
Scientific Consultant/Advisor: Mirum, Rectify, Shire, Albireo, Qing Bio Therapeutics, GenerationBio, Alnylam, Integra, Ipsen
Stock Options: GenerationBio
Data Safety Monitoring Board: Spruce

John M. Vierling, MD, FACP, FAASLD, AGAF:
Employee: Athenex, Inc.
Scientific Consultant/Advisor: AbbVie, Alexion, Arena, Blade, BristolMyers Squibb, CymaBay, Gilead, Durect, First Thoughts, Fractal, Ipsen, Kezar, LabCorp, Eli Lilly & Co., Inc., Madrigal, Mallinckrodt, Merck & Co., Inc, Moderna, New Horizons, Novartis, Ocalot Bio, SciGen, Takeda, Umecrine, HepQuant, UpToDate
Research Grant: AbbVie, Allergan, Alnlaym, Arena, Arrowhead, 89Bio, Blade, Celgene, Bristol Myers-Squibb, Conatus, CymaBay, Eiger, Eisai, Enanta, Escient, Evive, Galectant, Pfizer, Inc, Pliant, Protagonist, Sagamet, Sundise, Taiwan J, Tobira, Zydus

Michael Volk, MD, MSc, FAASLD:
Scientific Consultant/Advisor: BioVie, Inc.
Speakers Bureau: Salix

Please review the AASLD Privacy Policy before starting this course.
Powered By